Your browser doesn't support javascript.
loading
Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma.
Mian, Idrees; Milton, Denái R; Shah, Nina; Nieto, Yago; Popat, Uday R; Kebriaei, Partow; Parmar, Simrit; Oran, Betul; Shah, Jatin J; Manasanch, Elisabet E; Orlowski, Robert Z; Shpall, Elizabeth J; Champlin, Richard E; Qazilbash, Muzaffar H; Bashir, Qaiser.
Afiliação
  • Mian I; Internal Medicine Residency Program, The University of Texas Health Science Center at Houston, Houston, Texas.
  • Milton DR; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Shah N; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Nieto Y; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Popat UR; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kebriaei P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Parmar S; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Oran B; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Shah JJ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Manasanch EE; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Orlowski RZ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Shpall EJ; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Champlin RE; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Qazilbash MH; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bashir Q; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer ; 122(24): 3831-3837, 2016 Dec 15.
Article em En | MEDLINE | ID: mdl-27680710
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Talidomida / Inibidores da Angiogênese / Mieloma Múltiplo / Antineoplásicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Talidomida / Inibidores da Angiogênese / Mieloma Múltiplo / Antineoplásicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article